PAVmed Inc (PAVMZ) News

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

PAVmed and Lucid Diagnostics Provide Strategic Business Update

Strategic resource reallocation, including workforce reduction and other cost-cutting measures, to prioritize near-term Lucid and Veris Health...

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

Companies to host Conference Call at 4:30 PM EDT on Tuesday, January 17, 2023 PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage...

PAVmed Partners with Novosound on Ultrasound Imaging Technology

License option and joint R&D agreement seek to apply Novosound’s groundbreaking flexible thin-film ultrasound technology to intravascular...

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

Executes first commercial contract with leading New Jersey oncology practice PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified...

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and...

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

EsoCheck esophageal cell sampling procedure performed on 687 patients with 98% success rate Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a...

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

EsoGuard test volume increased 28% sequentially and 436% annually Conference call and webcast to be held today at 4:30 PM EDT Lucid Diagnostics...